Brief: Atossa Therapeutics Announces Updated Protocol For Clinical Trial Evaluating (Z)-Endoxifen In Combination With Abemaciclib (Verzenio®) In Women With Er+/Her2- Breast Cancer

Atossa Therapeutics

28/06/2024 13:46

June 28 (Reuters) - Atossa Therapeutics Inc  ATOS.O :
    * ATOSSA THERAPEUTICS ANNOUNCES UPDATED PROTOCOL FOR
CLINICAL
TRIAL EVALUATING (Z)-ENDOXIFEN IN COMBINATION WITH ABEMACICLIB
(VERZENIO®) IN WOMEN WITH ER+/HER2- BREAST CANCER
    * ATOSSA THERAPEUTICS INC - INCREASES (Z)-ENDOXIFEN DOSE TO
80 MG
IN PHASE 2 STUDY
    * ATOSSA THERAPEUTICS: STUDY IS NOW ENROLLING AN 80 MG PK
COHORT
    * ATOSSA THERAPEUTICS: COMBINATION STUDY WILL NOW ENROLL
APPROXIMATELY 80 PARTICIPANTS ACROSS TWO 40-PARTICIPANT COHORTS
    * ATOSSA THERAPEUTICS: CHANGE IN STUDY DOSE WAS DETERMINED
FOLLOWING A REVIEW OF SAFETY, EFFICACY AND PHARMACOKINETIC (PK)
DATA
    * ATOSSA THERAPEUTICS: DATA EXPECTED TO FURTHER VALIDATE
THAT
(Z)-ENDOXIFEN IS SAFE & HIGHLY EFFICACIOUS IN PREMENOPAUSAL
WOMEN WITHOUT NEED FOR OFS

Source text for Eikon:  ID:nGNX9yxg8f 
Further company coverage:  ATOS.O 

 ((Reuters.Briefs@thomsonreuters.com;))